Wolfe Research on Regeneron Pharma (REGN): 'Results were good'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
September 8, 2022 11:29 AM EDTNearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo
There are currently no approved medicines specifically indicated to treat prurigo nodularis;Â regulatory submissions for Dupixent are under Priority Review in the U.S. and under review in the European Union
22 Dupixent abstracts are being presented at the EADV 2022 Congress across four dermatological diseases with underlying type 2 inflammation
TARRYTOWN, N.Y. and PARIS,... More
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
September 8, 2022 9:01 AM EDT91% and 89% of diabetic macular edema (DME) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively
79% and 77% of wet age-related macular degeneration (wAMD) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively
Safety of aflibercept 8 mg consistent with the established safety profile of EYLEA® (aflibercept) Injection
TARRYTOWN, N.Y., Sept. 8, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.... More
